Median Technologies today announced the promising results of a first retrospective study on the implementation of the iBiopsy® platform for the analysis of patients with solid tumor cancer who are likely to be responsive to immuno-oncology treatments such as those based on immune checkpoint inhibitors (ICIs)
Read moreFirst-half revenue up 47.9% to €5.9 million, compared with €4.0 million in H1 2019 – 7 consecutive quarters of revenue growth – Order backlog to €53.6 million as of June 30th, 2020, up 40% compared with order backlog as of December 31st, 2019 and up 74.6% compared with order backlog as of June 30th, 2019 – Cash and cash equivalents expected to reach €19.4 million
Read moreMedian Technologies announced today that it has been awarded the Euronext European Rising Tech Label. The European Rising Tech Label recognizes 98 top-performing companies among more than 350 small and mid-caps listed on Euronext markets in Amsterdam, Brussels, Dublin, Lisbon and Paris, in the Tech sector (i.e., Life Sciences, Clean Tech and Technology, Media & Telecom).
Read moreMedian Technologies appoints Oern Stuge MD, MBA, to its Board of Directors. Oern Stuge brings to Median his tremendous expertise in the life sciences industry as well as his unique vision and experience in enterprise development including Go to Market strategy and Medtech company growth.
Read moreTo download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]